Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 13/20 | 0.64 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28124044 | 0.77 | MAPT (0.62) | PHGDHATRKDM4EALDH1A1LMNA | |
| SCHEMBL31610029 | 0.76 | L3MBTL1 (0.67) | DHX9ATRKDM4EALDH1A1LMNA | |
| SCHEMBL17593243 | 0.75 | KDM4E (0.62) | PHGDHMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25368211 | 0.75 | HPGD (0.65) | DHX9MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL30543903 | 0.75 | HPGD (0.65) | DHX9MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL31610122 | 0.75 | ATR (0.52) | DHX9ATRALDH1A1LMNA | |
| SCHEMBL25368740 | 0.75 | NR1H4 (0.68) | PHGDHDHX9ATRMEN1KMT2A | |
| SCHEMBL17592953 | 0.75 | PHGDH (0.59) | PHGDHKDM4EALDH1A1LMNA | |
| SCHEMBL26003806 | 0.75 | MEN1 (0.48) | PHGDHDHX9ATRMEN1KMT2A | |
| SCHEMBL31610145 | 0.75 | KCNK3 (0.72) | DHX9MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | PHGDH 805/4885DHX9 1/4885ATR 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.